Why it’s time to say goodbye to stavudine ... everywhere
The previous issue of the SAJHIV (December 2011) carried an Opinion piece by Innes, Cotton and Venter regarding the potential value of low-dose of stavudine (20 mg twice a day). They suggested that reduced dosing of stavudine may lead to levels of viral suppression comparable with those achieved wit...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AOSIS
2012-03-01
|
| Series: | Southern African Journal of HIV Medicine |
| Online Access: | https://sajhivmed.org.za/index.php/hivmed/article/view/155 |
| _version_ | 1811291693651066880 |
|---|---|
| author | Isabelle Andrieux-Meyer Polly Clayden Simon Collins Nathan Geffen Eric Goemaere Mark Harrington Sharonann Lynch Tido von Schoen-Angerer Tracy Swan |
| author_facet | Isabelle Andrieux-Meyer Polly Clayden Simon Collins Nathan Geffen Eric Goemaere Mark Harrington Sharonann Lynch Tido von Schoen-Angerer Tracy Swan |
| author_sort | Isabelle Andrieux-Meyer |
| collection | DOAJ |
| description | The previous issue of the SAJHIV (December 2011) carried an Opinion piece by Innes, Cotton and Venter regarding the potential value of low-dose of stavudine (20 mg twice a day). They suggested that reduced dosing of stavudine may lead to levels of viral suppression comparable with those achieved with stavudine 30 mg bd but with a lower risk of toxicity and side-effects, and at a fraction of the cost of tenofovir. The Opinion was related to a larger proposal, led by Venter, to conduct a head-to-head trial comparing low-dose stavudine with tenofovir (both in a regimen including lamivudine and efavirenz) on viral suppression and other treatment outcomes over 24 months. There has been considerable debate regarding the advantages and disadvantages of low-dose stavudine, and in turn the value of any such trial. Here the debate continues with a commentary by Isabelle Andrieux-Meyer et al. and a rebuttal by Venter and colleagues. |
| first_indexed | 2024-04-13T04:33:15Z |
| format | Article |
| id | doaj.art-6e64d0c010944281b53007e9edb682f2 |
| institution | Directory Open Access Journal |
| issn | 1608-9693 2078-6751 |
| language | English |
| last_indexed | 2024-04-13T04:33:15Z |
| publishDate | 2012-03-01 |
| publisher | AOSIS |
| record_format | Article |
| series | Southern African Journal of HIV Medicine |
| spelling | doaj.art-6e64d0c010944281b53007e9edb682f22022-12-22T03:02:15ZengAOSISSouthern African Journal of HIV Medicine1608-96932078-67512012-03-01131171910.4102/sajhivmed.v13i1.155155Why it’s time to say goodbye to stavudine ... everywhereIsabelle Andrieux-Meyer0Polly Clayden1Simon Collins2Nathan Geffen3Eric Goemaere4Mark Harrington5Sharonann Lynch6Tido von Schoen-Angerer7Tracy Swan8Médecins Sans Frontières Access CampaignHIV i-BaseHIV i-BaseTreatment Action CampaignMédecins Sans Frontières, South AfricaTreatment Action GroupMédecins Sans Frontières Access CampaignMédecins Sans Frontières Access CampaignTreatment Action GroupThe previous issue of the SAJHIV (December 2011) carried an Opinion piece by Innes, Cotton and Venter regarding the potential value of low-dose of stavudine (20 mg twice a day). They suggested that reduced dosing of stavudine may lead to levels of viral suppression comparable with those achieved with stavudine 30 mg bd but with a lower risk of toxicity and side-effects, and at a fraction of the cost of tenofovir. The Opinion was related to a larger proposal, led by Venter, to conduct a head-to-head trial comparing low-dose stavudine with tenofovir (both in a regimen including lamivudine and efavirenz) on viral suppression and other treatment outcomes over 24 months. There has been considerable debate regarding the advantages and disadvantages of low-dose stavudine, and in turn the value of any such trial. Here the debate continues with a commentary by Isabelle Andrieux-Meyer et al. and a rebuttal by Venter and colleagues.https://sajhivmed.org.za/index.php/hivmed/article/view/155 |
| spellingShingle | Isabelle Andrieux-Meyer Polly Clayden Simon Collins Nathan Geffen Eric Goemaere Mark Harrington Sharonann Lynch Tido von Schoen-Angerer Tracy Swan Why it’s time to say goodbye to stavudine ... everywhere Southern African Journal of HIV Medicine |
| title | Why it’s time to say goodbye to stavudine ... everywhere |
| title_full | Why it’s time to say goodbye to stavudine ... everywhere |
| title_fullStr | Why it’s time to say goodbye to stavudine ... everywhere |
| title_full_unstemmed | Why it’s time to say goodbye to stavudine ... everywhere |
| title_short | Why it’s time to say goodbye to stavudine ... everywhere |
| title_sort | why it s time to say goodbye to stavudine everywhere |
| url | https://sajhivmed.org.za/index.php/hivmed/article/view/155 |
| work_keys_str_mv | AT isabelleandrieuxmeyer whyitstimetosaygoodbyetostavudineeverywhere AT pollyclayden whyitstimetosaygoodbyetostavudineeverywhere AT simoncollins whyitstimetosaygoodbyetostavudineeverywhere AT nathangeffen whyitstimetosaygoodbyetostavudineeverywhere AT ericgoemaere whyitstimetosaygoodbyetostavudineeverywhere AT markharrington whyitstimetosaygoodbyetostavudineeverywhere AT sharonannlynch whyitstimetosaygoodbyetostavudineeverywhere AT tidovonschoenangerer whyitstimetosaygoodbyetostavudineeverywhere AT tracyswan whyitstimetosaygoodbyetostavudineeverywhere |